Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Last Updated: May 29, 2023

Patent: 9,970,059

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 9,970,059
Title:Survival predictor for diffuse large B cell lymphoma
Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.
Inventor(s): Rimsza; Lisa (Tucson, AZ), Lister; Andrew T. (London, GB), Chan; Wing C. (Omaha, NE), Weisenburger; Dennis (Elkhorn, NE), Delabie; Jan (Oslo, NO), Smeland; Erlend B. (Oslo, NO), Holte; Harald (Oslo, NO), Kvaloy; Stein (Oslo, NO), Braziel; Rita M. (West Linn, OR), Fisher; Richard I. (Pittsford, NY), Jares; Pedro (Barcelona, ES), Lopez-Guillermo; Armando (Barcelona, ES), Guerri; Elias Campo (Barcelona, ES), Jaffe; Elaine S. (Great Falls, VA), Lenz; Georg (Berlin, DE), Wilson; Wyndham H. (Washington, DC), Wright; George (Rockville, MD), Dave; Sandeep S. (Chapel Hill, NC), Staudt; Louis M. (Bethesda, MD), Gascoyne; Randy D. (North Vancouver, CA), Connors; Joseph M. (Vancouver, CA), Muller-Hermelink; Hans-Konrad (Wrzburg, DE), Rosenwald; Andreas (Wuerzburg, DE), Ott; German (Bietigheim-Bissingen, DE)
Assignee: The United States of America, as represented by the Secretary, Department of Human Services (Washington, DC) Arizona Board of Regents on behalf of the University of Arizona (Tucson, AZ) Queen Mary University of London (London, GB) Board of Regents of the University of Nebraska (Lincoln, NE) Oslo University Hospital HF (Oslo, NO) Oregon Health & Science University (Portland, OR) University of Rochester (Rochester, NY) Hospital Clinic de Barcelona (Barcelona, ES) Universitat de Barcelona (Barcelona, ES) British Columbia Cancer Agency Branch (Vancouver, CA) Julius-Maximilians-University of Wurzburg (Wurzburg, DE)
Application Number:14/540,302
Patent Claims:see list of patent claims

Details for Patent 9,970,059

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2028-06-06
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 06/22/2017 ⤷  Try a Trial 2028-06-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.